Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | EDNRB | P24530 | 3/20 | 0.48 |
| ▸ | EDNRA | P25101 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | CYTH2 | Q99418 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24310041 | 0.82 | TSHR (0.58) | TSHRNPSR1SMN1; SMN2GAAPKM | |
| SCHEMBL24309338 | 0.81 | TSHR (0.60) | TSHRNPSR1SMN1; SMN2GAAPKM | |
| SCHEMBL24309709 | 0.76 | TSHR (0.55) | TSHRNPSR1SMN1; SMN2GAAPKM | |
| SCHEMBL29567271 | 0.75 | TSHR (0.50) | TSHRNPSR1SMN1; SMN2GAAPKM | |
| SCHEMBL24309359 | 0.75 | TSHR (0.50) | TSHRNPSR1SMN1; SMN2GAAPKM | |
| SCHEMBL24309401 | 0.75 | TSHR (0.66) | TSHRNPSR1SMN1; SMN2GAAPKM | |
| SCHEMBL6670440 | 0.74 | TSHR (1.00) | TSHRNPSR1SMN1; SMN2GAAPKM | |
| SCHEMBL24309337 | 0.73 | NPSR1 (0.51) | TSHRNPSR1PKMMAPTALDH1A1 | |
| SCHEMBL24309650 | 0.72 | NPSR1 (0.50) | TSHRNPSR1MAPTALDH1A1HSD11B1 | |
| SCHEMBL29516232 | 0.71 | TSHR (0.56) | TSHRNPSR1SMN1; SMN2GAAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | TSHR 1755/4885NPSR1 3974/4885SMN1; SMN2 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.